TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has shared an announcement.
Zhaoke Ophthalmology Limited announced the approval of its Investigational New Drug application for PAN-90806, an innovative eye drop for treating wet age-related macular degeneration, by China’s National Medical Products Administration. Additionally, the company received marketing authorization for Epinastine HCl eye drops for allergic conjunctivitis. These developments are expected to enhance the company’s market position by offering less invasive treatment options and addressing significant market needs in China, where the wAMD drug market is projected to grow substantially.
The most recent analyst rating on (HK:6622) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Zhaoke Ophthalmology Ltd. stock, see the HK:6622 Stock Forecast page.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company focused on the ophthalmology industry, specializing in the development and commercialization of eye care products. The company is involved in creating treatments for conditions such as age-related macular degeneration and allergic conjunctivitis, with a market focus on China and potentially global markets.
Average Trading Volume: 1,570,575
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.7B
Find detailed analytics on 6622 stock on TipRanks’ Stock Analysis page.